Cell-Based Therapies in Skeletal Muscle Disease

Vallese, Denis; Yada, Erica; Butler-Browne, Gillian; Mouly, Vincent

doi:10.1016/b978-0-12-381510-1.00077-6

Cited by 1 publication

(1 citation statement)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A promising cell candidate for systemic stem cell therapies are mesoangioblasts (MABs), mesenchymal stem cells from the walls of large vessels such as the dorsal aorta or arteries. MABs have the capability to exit the vessel site via transendothelial migration and migrate towards dysfunctional muscle fibers, where they improve muscle regeneration and support the expression of functional dystrophin [6,7]. MABs can be isolated from muscle biopsies, can be cultivated in high numbers, and offer the safety of an intra-arterial stem cell therapy as confirmed previously [8,9].…”

Section: Introductionmentioning

confidence: 75%

Development of a biofabricated 3D in vitro vessel model for investigating transendothelial migration in stem cell therapy

Wachendörfer,

Palkowitz,

Fischer

2024

Biofabrication

View full text Add to dashboard Cite

Systemic stem cell therapies hold promise for treating severe diseases, but their efficiency is hampered by limited migration of injected stem cells across vascular endothelium towards diseased tissues. Understanding transendothelial migration is crucial for improving therapy outcomes. We propose a novel 3D in vitro vessel model that aids to unravel these mechanisms and thereby facilitates stem cell therapy development. Our model simulates inflammation through cytokine diffusion from the tissue site into the vessel. It consists of a biofabricated vessel embedded in a fibrin hydrogel, mimicking arterial wall composition with smooth muscle cells and fibroblasts. The perfusable channel is lined with a functional endothelium which expresses vascular endothelial cadherin, provides an active barrier function, aligns with flow direction and is reconstructed by in situ two-photon-microscopy. Inflammatory cytokine release (tumor necrosis factor α, stromal-derived factor 1) is demonstrated in both a transwell assay and the 3D model. In proof-of-principle experiments, mesoangioblasts, known as a promising candidate for a stem cell therapy against muscular dystrophies, are injected into the vessel model, showing shear-resistant endothelial adhesion under capillary-like flow conditions. Our 3D in vitro model offers significant potential to study transendothelial migration mechanisms of stem cells, facilitating the development of improved stem cell therapies.

show abstract